These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 24266618)

  • 41. Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains.
    Himmel DM; Das K; Clark AD; Hughes SH; Benjahad A; Oumouch S; Guillemont J; Coupa S; Poncelet A; Csoka I; Meyer C; Andries K; Nguyen CH; Grierson DS; Arnold E
    J Med Chem; 2005 Dec; 48(24):7582-91. PubMed ID: 16302798
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
    Ragno R; Artico M; De Martino G; La Regina G; Coluccia A; Di Pasquali A; Silvestri R
    J Med Chem; 2005 Jan; 48(1):213-23. PubMed ID: 15634015
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
    Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
    ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.
    Tucker TJ; Sisko JT; Tynebor RM; Williams TM; Felock PJ; Flynn JA; Lai MT; Liang Y; McGaughey G; Liu M; Miller M; Moyer G; Munshi V; Perlow-Poehnelt R; Prasad S; Reid JC; Sanchez R; Torrent M; Vacca JP; Wan BL; Yan Y
    J Med Chem; 2008 Oct; 51(20):6503-11. PubMed ID: 18826204
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations.
    Rodríguez-Barrios F; Gago F
    J Am Chem Soc; 2004 Dec; 126(47):15386-7. PubMed ID: 15563158
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Revealing interaction mode between HIV-1 reverse transcriptase and diaryltriazine analog inhibitor.
    Li Z; Han J; Chen HF
    Chem Biol Drug Des; 2008 Nov; 72(5):350-9. PubMed ID: 19012571
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Das K; Lewi PJ; Hughes SH; Arnold E
    Prog Biophys Mol Biol; 2005 Jun; 88(2):209-31. PubMed ID: 15572156
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
    Chan JH; Freeman GA; Tidwell JH; Romines KR; Schaller LT; Cowan JR; Gonzales SS; Lowell GS; Andrews CW; Reynolds DJ; St Clair M; Hazen RJ; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Koszalka GW; Boone LR
    J Med Chem; 2004 Feb; 47(5):1175-82. PubMed ID: 14971897
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA.
    Wang J; Kang X; Kuntz ID; Kollman PA
    J Med Chem; 2005 Apr; 48(7):2432-44. PubMed ID: 15801834
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemometrical identification of mutations in HIV-1 reverse transcriptase conferring resistance or enhanced sensitivity to arylsulfonylbenzonitriles.
    Rodríguez-Barrios F; Gago F
    J Am Chem Soc; 2004 Mar; 126(9):2718-9. PubMed ID: 14995186
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CoMFA 3D-QSAR analysis of HIV-1 RT nonnucleoside inhibitors, TIBO derivatives based on docking conformation and alignment.
    Zhou Z; Madura JD
    J Chem Inf Comput Sci; 2004; 44(6):2167-78. PubMed ID: 15554687
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
    Sweeney ZK; Harris SF; Arora SF; Javanbakht H; Li Y; Fretland J; Davidson JP; Billedeau JR; Gleason SK; Hirschfeld D; Kennedy-Smith JJ; Mirzadegan T; Roetz R; Smith M; Sperry S; Suh JM; Wu J; Tsing S; Villaseñor AG; Paul A; Su G; Heilek G; Hang JQ; Zhou AS; Jernelius JA; Zhang FJ; Klumpp K
    J Med Chem; 2008 Dec; 51(23):7449-58. PubMed ID: 19007201
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future.
    De Clercq E
    Chem Biodivers; 2004 Jan; 1(1):44-64. PubMed ID: 17191775
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
    Hopkins AL; Ren J; Milton J; Hazen RJ; Chan JH; Stuart DI; Stammers DK
    J Med Chem; 2004 Nov; 47(24):5912-22. PubMed ID: 15537346
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis, biological activity and docking study of imidazol-5-one as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Mokale SN; Lokwani D; Shinde DB
    Bioorg Med Chem; 2012 May; 20(9):3119-27. PubMed ID: 22480850
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Murugesan V; Tiwari VS; Saxena R; Tripathi R; Paranjape R; Kulkarni S; Makwana N; Suryawanshi R; Katti SB
    Bioorg Med Chem; 2011 Nov; 19(22):6919-26. PubMed ID: 21982685
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors.
    Auwerx J; Esnouf R; De Clercq E; Balzarini J
    Mol Pharmacol; 2004 Jan; 65(1):244-51. PubMed ID: 14722257
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis and biological evaluation of N-acetyl-beta-aryl-1,2-didehydroethylamines as new HIV-1 RT inhibitors in vitro.
    Cheng P; Jiang ZY; Wang RR; Zhang XM; Wang Q; Zheng YT; Zhou J; Chen JJ
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4476-80. PubMed ID: 17574419
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular matchmaking: NNRTIs can enhance the dimerization of HIV type 1 reverse transcriptase.
    Hughes SH
    Proc Natl Acad Sci U S A; 2001 Jun; 98(13):6991-2. PubMed ID: 11416176
    [No Abstract]   [Full Text] [Related]  

  • 60. Thermodynamics of HIV-1 reverse transcriptase in action elucidates the mechanism of action of non-nucleoside inhibitors.
    Bec G; Meyer B; Gerard MA; Steger J; Fauster K; Wolff P; Burnouf D; Micura R; Dumas P; Ennifar E
    J Am Chem Soc; 2013 Jul; 135(26):9743-52. PubMed ID: 23742167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.